Previous Close | 4.6000 |
Open | 4.7800 |
Bid | 5.2300 x 1200 |
Ask | 5.7500 x 1000 |
Day's Range | 4.4100 - 5.5000 |
52 Week Range | 4.4100 - 44.8000 |
Volume | |
Avg. Volume | 18,678 |
Market Cap | 3.299M |
Beta (5Y Monthly) | 0.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -33.6300 |
Earnings Date | May 10, 2024 - May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 240.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for BPTH
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript March 8, 2024 Bio-Path Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Full Year 2023 Earnings Conference Call. […]
Q4 2023 Bio Path Holdings Inc Earnings Call
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the year ended December 31, 2023 and provided an update on recent corporate developments. “2023 was a year of focused execution, as evidenced by the continued